|1.||Sloan, Sheldon: 10 articles (04/2014 - 06/2002)|
|2.||Fujimoto, Kazuma: 8 articles (05/2015 - 10/2005)|
|3.||Robinson, M: 8 articles (11/2003 - 05/2001)|
|4.||Kinoshita, Yoshikazu: 7 articles (05/2015 - 01/2003)|
|5.||Hongo, Michio: 7 articles (05/2012 - 12/2010)|
|6.||Humphries, T J: 7 articles (02/2003 - 04/2000)|
|7.||Higuchi, Kazuhide: 6 articles (11/2015 - 01/2003)|
|8.||Kinoshita, Y: 6 articles (10/2014 - 08/2000)|
|9.||Fujiwara, Yasuhiro: 6 articles (01/2013 - 01/2003)|
|10.||Kusano, Motoyasu: 6 articles (01/2013 - 03/2011)|
|1.||Gastroesophageal Reflux (GERD)
03/01/2002 - "In this large, open-label trial, rabeprazole rapidly and effectively relieved gastro-oesophageal reflux disease symptoms in most patients with erosive oesophagitis. "
04/01/2014 - "Rabeprazole was effective in maintaining endoscopic/histologic healing during a 24-week maintenance period in children with endoscopically proven GERD. "
09/01/2010 - "Rabeprazole was again significantly effective in patients with positive findings for esophageal reflux (p = 0.0025). "
05/01/2008 - "The addition of rabeprazole offered significant improvement in GERD scores in both groups."
07/01/2007 - "Rabeprazole was significantly more effective in erosive GERD than in NERD patients. "
05/01/2010 - "The primary efficacy end point, mean percentage of heartburn-free days, was significantly greater with rabeprazole vs. placebo: 82.58% and 62.17% (ITT; P < 0.0001) [per protocol 86.74% rabeprazole vs. 74.93% placebo (P < 0.0254)]. "
06/01/2002 - "After a 2-wk, single-blind placebo run-in phase, patients were randomized to receive 10 mg or 20 mg of rabeprazole or placebo once daily for 4 wk. Rabeprazole rapidly and effectively relieved heartburn, with significant improvements on day 1 of dosing. "
08/01/2000 - "Rabeprazole was also significantly more effective than placebo in preventing relapse of day-and night-time heartburn severity, maintaining overall patient well-being, and reducing antacid use. "
08/01/2000 - "There were also significant differences between the two groups favoring rabeprazole with respect to resolution or improvement of heartburn symptoms and improvement in sense of well-being. "
08/01/2011 - "Administration of 5 mg and 10 mg rabeprazole sufficiently inhibited pathological gastroesophageal acid reflux and relieved heartburn episodes in NERD patients who did not respond to an antacid. "
11/01/2003 - "pylori infection were recruited for this controlled, randomized, open and parallel-group trial comparing the efficacy of two durations of the same rabeprazole-based triple therapy. "
12/01/2003 - "Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype."
09/01/2001 - "Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism."
03/21/2005 - "Our study showed the eradication rates against H pylori infection 3 and 12 mo after triple therapy were not different between the 3-d and 7-d rabeprazole-based groups. "
11/01/2003 - "The aim of this study was to assess whether there is the possibility of shortening a rabeprazole-based triple therapy from 7 to 4 days without compromising its efficacy in the eradication of Helicobacter pylori infection. "
|4.||Peptic Ulcer (Peptic Ulcers)
05/01/2015 - "The aim of this study is to assess the long-term efficacy and safety of rabeprazole for preventing peptic ulcer recurrence on LDA therapy. "
10/01/2014 - "To conduct a randomised, double-blind, triple-dummy, active-controlled, multicentre trial, named the PLANETARIUM study, to assess the efficacy, dose-response relationship and safety of rabeprazole for peptic ulcer recurrence in Japanese patients on long-term LDA therapy. "
04/01/2005 - "To study the efficacy and safety of rabeprazole in peptic ulcer patients alone or combined with anti-Helicobacter pylori (Hp) agents. "
05/01/2015 - "Recurrent peptic ulcers were not observed in the newly-initiated rabeprazole 10- and 5-mg groups. "
05/01/2015 - "The full analysis set consisted of 151 and 150 subjects in the long-term rabeprazole 10- and 5-mg groups, respectively, and the cumulative recurrence rates of peptic ulcers were 2.2 and 3.7%, respectively. "
|5.||Duodenal Ulcer (Curling's Ulcer)
01/01/2004 - "[Selecting variants of drug treatment of non-complicated duodenal ulcer (based on a study of results of Rabeprazole efficiency)]."
09/01/2002 - "Rabeprazole (10 mg/day) has excellent therapeutic effect on the symptoms of duodenal ulcer patients. "
04/01/2002 - "[Regeneration of the gastric epitheliocytes during treatment of duodenal ulcer with pariet]."
01/01/2002 - "In the article the results of the eradication therapy by Pariet in the patients suffering from the duodenal ulcer disease, associated with Helicobacter pylori (HP), are estimated. "
04/01/2000 - "Rabeprazole is an effective and well-tolerated alternative treatment for patients with active duodenal ulcer disease."
|2.||Proton Pumps (Proton Pump)
|8.||Proton Pump Inhibitors
|3.||Complementary Therapies (Alternative Medicine)